Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by
assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective doses
of aspirin (325 mg) in normal healthy volunteers.